Our data on higher sensitivity of iATP in comparison to CD4+-cell counts is well in line with initial reports of natalizumab-associated PML where no aberrant leukocyte/lymphocyte cell counts were evident [27]–[29]. Here, CD4 is linked to progressive multifocal leukoencephalopathy.